| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
|
Fennell, Dean A
|
|
|
23 |
3 |
p. 374-381
|
artikel
|
| 2 |
A comprehensive framework for early-onset colorectal cancer research
|
Eng, Cathy
|
|
|
23 |
3 |
p. e116-e128
|
artikel
|
| 3 |
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
|
|
|
|
23 |
3 |
p. 382-392
|
artikel
|
| 4 |
Bangladesh decentralises cancer care services to expand access to care
|
Das, Manjulika
|
|
|
23 |
3 |
p. e104
|
artikel
|
| 5 |
Climate crisis and cancer: perspectives from the hardest hit
|
Eala, Michelle Ann B
|
|
|
23 |
3 |
p. e92
|
artikel
|
| 6 |
Code of practice needed for samples donated by trial participants
|
Coleman, Robert
|
|
|
23 |
3 |
p. e89-e90
|
artikel
|
| 7 |
Code of practice needed for samples donated by trial participants – Sponsor's reply
|
Warner, Doug
|
|
|
23 |
3 |
p. e91
|
artikel
|
| 8 |
Correction to Lancet Oncol 2022; 23: 207–08
|
|
|
|
23 |
3 |
p. e101
|
artikel
|
| 9 |
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?
|
Antonarelli, Gabriele
|
|
|
23 |
3 |
p. 325-328
|
artikel
|
| 10 |
Essential medicines list in national cancer control plans: a secondary analysis from a global study
|
Razis, Evangelia
|
|
|
23 |
3 |
p. e144-154
|
artikel
|
| 11 |
Frontline chemotherapy-free induction for mantle cell lymphoma
|
Vitolo, Umberto
|
|
|
23 |
3 |
p. 321-322
|
artikel
|
| 12 |
Gender disparities in access to paediatric cancer care in India
|
Das, Manjulika
|
|
|
23 |
3 |
p. 336
|
artikel
|
| 13 |
Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study
|
Saad, Mohamad
|
|
|
23 |
3 |
p. 341-352
|
artikel
|
| 14 |
Genetic risk of cancer: a tale of diversity from the Middle East
|
Al-Kuraya, Khawla S
|
|
|
23 |
3 |
p. 318-319
|
artikel
|
| 15 |
Granulocyte colony-stimulating factor-associated aortitis
|
Takahashi, Toshiaki
|
|
|
23 |
3 |
p. e155
|
artikel
|
| 16 |
HLA-A*03 and response to immune checkpoint blockade in patients with cancer
|
Diamantopoulos, Leonidas N
|
|
|
23 |
3 |
p. e99
|
artikel
|
| 17 |
IAEA and Brazilian Navy to provide new arsenal to fight breast cancer: mammography on a ship
|
Triunfol, Marcia
|
|
|
23 |
3 |
p. e103
|
artikel
|
| 18 |
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
|
Wang, Michael L
|
|
|
23 |
3 |
p. 406-415
|
artikel
|
| 19 |
Importing oncology trials from China: a bridge over troubled waters?
|
Singh, Harpreet
|
|
|
23 |
3 |
p. 323-325
|
artikel
|
| 20 |
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
|
Richardson, Paul G
|
|
|
23 |
3 |
p. 416-427
|
artikel
|
| 21 |
Malaysia to ban tobacco sales to people born after 2005
|
Das, Manjulika
|
|
|
23 |
3 |
p. 331
|
artikel
|
| 22 |
Medical treatment for active breast cancer brain metastases
|
Bailleux, Caroline
|
|
|
23 |
3 |
p. 319-321
|
artikel
|
| 23 |
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting
|
Becerra-Chauca, Naysha
|
|
|
23 |
3 |
p. e100
|
artikel
|
| 24 |
Mozambique takes on cancer burden challenges
|
Das, Manjulika
|
|
|
23 |
3 |
p. 334
|
artikel
|
| 25 |
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study
|
Grey, Alistair D R
|
|
|
23 |
3 |
p. 428-438
|
artikel
|
| 26 |
New agreement to strengthen paediatric cancer treatment in Libya
|
Das, Manjulika
|
|
|
23 |
3 |
p. 332
|
artikel
|
| 27 |
NICE withdraws quality standard on colorectal cancer treatment after “lack of consensus”
|
Wilkinson, Emma
|
|
|
23 |
3 |
p. 333
|
artikel
|
| 28 |
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
|
Smith, Matthew R
|
|
|
23 |
3 |
p. 362-373
|
artikel
|
| 29 |
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
|
Thiery-Vuillemin, Antoine
|
|
|
23 |
3 |
p. 393-405
|
artikel
|
| 30 |
Post-protocol therapy and informative censoring in the CANDOR study
|
Meirson, Tomer
|
|
|
23 |
3 |
p. e97
|
artikel
|
| 31 |
Post-protocol therapy and informative censoring in the CANDOR study – Authors' reply
|
Usmani, Saad Z
|
|
|
23 |
3 |
p. e98
|
artikel
|
| 32 |
President Biden outlines plans for Cancer Moonshot 2.0
|
Gourd, Elizabeth
|
|
|
23 |
3 |
p. 335
|
artikel
|
| 33 |
Progression-free survival: it is time for a new name
|
Gyawali, Bishal
|
|
|
23 |
3 |
p. 328-330
|
artikel
|
| 34 |
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
|
Yan, Min
|
|
|
23 |
3 |
p. 353-361
|
artikel
|
| 35 |
Reflections on the past
|
The Lancet Oncology,
|
|
|
23 |
3 |
p. 317
|
artikel
|
| 36 |
Retraction and republication—Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
|
The Editors of The Lancet Oncology,
|
|
|
23 |
3 |
p. 330
|
artikel
|
| 37 |
ROAR trial: which treatment is effective after progression?
|
Sütcüoğlu, Osman
|
|
|
23 |
3 |
p. e93
|
artikel
|
| 38 |
ROAR trial: which treatment is effective after progression? – Authors' reply
|
Wen, Patrick Y
|
|
|
23 |
3 |
p. e94
|
artikel
|
| 39 |
Sentinel nodes and breast cancer: an old story
|
Drouin, Emmanuel
|
|
|
23 |
3 |
p. 340
|
artikel
|
| 40 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
|
Zhu, Xiaofei
|
|
|
23 |
3 |
p. e105-e115
|
artikel
|
| 41 |
Still Max: Max Dean asks how we can fix ourselves
|
Lucas, Catherine
|
|
|
23 |
3 |
p. 339
|
artikel
|
| 42 |
Survivorship after neoadjuvant chemotherapy
|
Zhang, Jin
|
|
|
23 |
3 |
p. e95
|
artikel
|
| 43 |
Survivorship after neoadjuvant chemotherapy – Authors' reply
|
Yau, Christina
|
|
|
23 |
3 |
p. e96
|
artikel
|
| 44 |
Toxicity and efficacy of chronomodulated chemotherapy: a systematic review
|
Printezi, Markella I
|
|
|
23 |
3 |
p. e129-e143
|
artikel
|
| 45 |
US Congress considers new health-care bill for burn pit-exposed veterans
|
Furlow, Bryant
|
|
|
23 |
3 |
p. e102
|
artikel
|
| 46 |
Yale Precision Medicine Tumor Board: reawakening the guardian of the genome
|
Grant, Michael J
|
|
|
23 |
3 |
p. 337-338
|
artikel
|
Tijdschrift beschrijving